home / stock / avctf / avctf quote
Last: | $0.59 |
---|---|
Change Percent: | 0.0% |
Open: | $0.59 |
Close: | $0.59 |
High: | $0.59 |
Low: | $0.59 |
Volume: | 110 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.59 | $0.59 | $0.59 | $0.59 | $0.59 | 110 | 04-25-2024 |
$0.5906 | $0.5906 | $0.5906 | $0.5906 | $0.5906 | 700 | 04-04-2024 |
$0.624 | $0.6666 | $0.624 | $0.6666 | $0.624 | 254 | 04-01-2024 |
$0.66 | $0.66 | $0.66 | $0.66 | $0.66 | 1,005 | 03-18-2024 |
$0.6664 | $0.6664 | $0.6664 | $0.6664 | $0.6664 | 1,000 | 03-01-2024 |
$0.6811 | $0.6811 | $0.6811 | $0.6811 | $0.6811 | 400 | 02-29-2024 |
$0.9062 | $0.878 | $0.9062 | $0.9065 | $0.878 | 16,000 | 02-28-2024 |
$1.62 | $0 | $1.62 | $0 | $0 | 90 | 01-24-2024 |
$1.62 | $0 | $1.62 | $0 | $0 | 10,000 | 01-08-2024 |
$1.62 | $0 | $1.62 | $0 | $0 | 1,300 | 12-22-2023 |
$1.62 | $1.62 | $1.62 | $1.62 | $1.62 | 1,000 | 12-13-2023 |
$1.73 | $1.73 | $1.73 | $1.73 | $1.73 | 51,729 | 12-06-2023 |
$2.17 | $2.17 | $2.17 | $2.17 | $2.17 | 100 | 12-05-2023 |
$1.67 | $1.67 | $1.67 | $1.67 | $1.67 | 2,000 | 12-01-2023 |
$1.58 | $1.58 | $1.58 | $1.58 | $1.58 | 1,800 | 11-29-2023 |
$1.58 | $1.58 | $1.58 | $1.58 | $1.58 | 150 | 11-23-2023 |
$1.58 | $1.58 | $1.58 | $1.58 | $1.58 | 150 | 11-22-2023 |
$1.62 | $1.98 | $1.62 | $1.98 | $1.62 | 5,146 | 11-14-2023 |
$1.98 | $1.99 | $1.98 | $1.99 | $1.98 | 11,055 | 11-13-2023 |
$1.99 | $1.99 | $1.99 | $1.99 | $1.99 | 100 | 10-23-2023 |
News, Short Squeeze, Breakout and More Instantly...
Avacta Group PLC Company Name:
AVCTF Stock Symbol:
OTCMKTS Market:
5 April 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) AVA6000 Abstract Release by AACR and Full Presentation Update Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology dru...
5 March 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Resear...
19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals commercial emphasis for Avacta to leverage clinical progress Avacta Group plc (AIM: AVCT...